Allison Kerr, MD
Endocrinology, Diabetes & Metabolism · Clinton, MDNPI 1851317473
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.5% of the total across 457 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 14.0% — the pattern of someone who eats at a lot of different presentations.
Across 457 payments — averaging $18.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amneal Pharmaceuticals LLC$1K
- Corcept Therapeutics$1K
- Lilly USA, LLC$982
- Novo Nordisk$704
- AstraZeneca$531
- Xeris Pharmaceuticals, Inc.$474
- plus $4K from 24 others
What the payments were for
- Food & beverage$8,51899%
- Education$1281%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amneal Pharmaceuticals LLC | 67 | $1,209 |
| Corcept Therapeutics | 49 | $1,064 |
| Lilly USA, LLC | 56 | $982 |
| Novo Nordisk | 38 | $704 |
| AstraZeneca(2 entities) | 29 | $531 |
| Xeris Pharmaceuticals, Inc. | 29 | $474 |
| Sanofi-aventis U.S. LLC | 28 | $468 |
| Medtronic(2 entities) | 18 | $341 |
| Insulet Corporation | 16 | $328 |
| Cequr Corporation | 3 | $277 |
| Mannkind Corporation | 14 | $242 |
| Abbott | 11 | $236 |
| Bayer | 16 | $225 |
| Boehringer Ingelheim | 10 | $209 |
| Johnson & Johnson | 14 | $189 |
| Merck | 11 | $180 |
| Dexcom, Inc. | 8 | $179 |
| AbbVie | 8 | $167 |
| Madrigal Pharmaceuticals | 5 | $121 |
| Recordati_rare_diseases_inc. | 6 | $118 |
| Amgen | 5 | $103 |
| Tandem Diabetes Care, Inc. | 4 | $82 |
| Amarin Pharma, Inc. | 4 | $65 |
| Sequel Med Tech, LLC | 2 | $56 |
| Ascendis Pharma Endocrinology Inc | 1 | $22 |
| Pfizer | 1 | $19 |
| Novartis | 1 | $16 |
| Zealand Pharma US, Inc. | 1 | $14 |
| BETA Bionics, Inc. | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CeQur Simplicity$224
How this compares
$8,646 in reported general payments places this provider in the 80th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
See all endocrinology, diabetes & metabolism providers in Maryland →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 185 | $259,693 |
| MounjaroTirzepatide | 119 | $185,768 |
| TrulicityDulaglutide | 56 | $103,386 |
| JardianceEmpagliflozin | 86 | $83,969 |
| GlyxambiEmpagliflozin/Linagliptin | 73 | $70,817 |
| RybelsusSemaglutide | 37 | $47,117 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 58 | $41,326 |
| Tresiba Flextouch U-100Insulin Degludec | 50 | $38,735 |
| FarxigaDapagliflozin Propanediol | 43 | $29,690 |
| JanuviaSitagliptin Phosphate | 18 | $25,580 |
| Tresiba Flextouch U-200Insulin Degludec | 23 | $24,050 |
| Humalog Kwikpen U-200Insulin Lispro | 21 | $22,903 |
| TradjentaLinagliptin | 13 | $14,838 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 16 | $10,286 |
| Humalog Kwikpen U-100Insulin Lispro | 31 | $10,070 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $704 | $306,811222 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $982 | $295,149207 claims |
| Boehringer IngelheimJardiance, Glyxambi, Tradjenta | $209 | $169,625172 claims |
| AstraZenecaFarxiga | $531 | $29,69043 claims |
| MerckJanuvia | $180 | $25,58018 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $468 | $10,28616 claims |
| Amneal Pharmaceuticals LLCUnithroid, Levothyroxine Sodium | $1,209 | $6,021252 claims |
| AbbVieSynthroid | $167 | $4,42249 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
Other endocrinology, diabetes & metabolism in Clinton
- Daniel GozziSuitland$1.2M
- Martin SarkarFrederick$1.1M
- Nicholas ArgentoLaurel$1.1M
- Romeu AzevedoCamp Springs$987K
- David BrownRockville$497K
- Philip LevinBaltimore$489K
- Helena RodbardRockville$468K
- Roy PhillipsBel Air$208K
- Eyob MakonnenAnnapolis$205K
- Jawaad KhokharGlen Burnie$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.